论文部分内容阅读
就乙/丙型病毒性肝炎的治疗而言,α干扰素仍是目前公认的主要抗病毒药物,其对乙型肝炎HBeAg及HBVDNA的阴转率约为40%,对丙型肝炎的疗效还要低一点,所以寻找新的抗病毒治疗方法仍为当务之急,分述如下:1 联合治疗乙/丙型肝炎目前在大多数国家,α干扰素是唯一被批准用于治疗慢性病毒性肝炎的药物,给予一个标准的干扰素疗程,有效率在30%~40%之间。在预测α干扰素治疗丙型肝炎疗效方面,目前多数学者认为血清HCVRNA水平及HCV基因型可资参
In terms of the treatment of hepatitis B / C virus, alpha interferon is still the currently recognized major antiviral drug with a negative conversion rate of about 40% for hepatitis B and HBVDNA. The therapeutic effect on hepatitis C is also Lower, so looking for a new antiviral treatment is still a top priority, are as follows: 1 combination treatment of hepatitis B / hepatitis C In most countries, IFN-α is currently the only drug approved for the treatment of chronic viral hepatitis, Give a standard interferon treatment, the efficiency of 30% to 40%. In predicting the efficacy of interferon-alpha in the treatment of hepatitis C, most scholars believe that serum HCV RNA levels and HCV genotypes are available